In an interview with Neuron, Dr. Ehlers, the Executive Vice President for Research and Development at Biogen, discusses the big questions to be answered in the field of therapeutic discovery and development. Read his insights on therapeutic approaches to impact neurodegenerative diseases as well as his story of an inadvertent discovery.
Michael Ehlers is Executive Vice President for Research & Development at Biogen, a leading biotechnology company. Dr. Ehlers grew up rural Nebraska and earned his bachelor's degree in chemistry from Caltech. He holds MD and PhD degrees from the Johns Hopkins University School of Medicine, where he trained with Rick Huganir. Prior to joining Biogen in 2016, Dr. Ehlers was Senior Vice President for BioTherapeutics and Chief Scientific Officer for Neuroscience at Pfizer, where he led the transformation of the Neuroscience and Rare Disease portfolios, successfully bringing 22 compounds into the clinic, as well as directing global activities in biologics design, synthesis, and production. Before entering his industry career in 2010, Dr. Ehlers was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. Dr. Ehlers' current research focuses on the interface between neuronal cell biology, the plasticity of neural circuits, and neurological disease. At Biogen, Dr. Ehlers oversees global research and development including discovery sciences, drug design, translational medicine, clinical development, medical affairs, and business development with a focus on neurological diseases.
What do you think are the big questions to be answered next in your field? In my area of therapeutic discovery and development, some big questions to be answered include whether and when neurodegenerative diseases can be slowed or stopped, how human brain circuits are modified by disease state and therapeutic interventions, and how genetics and endophenotypes will radically change the diagnostic categories of neurological and psychiatric disease.
Which aspect of science, your field or in general, would you wish the general public knew more about? I wish the general public knew more about how important very basic science is as the foundation of innovation, whether it be new medicines, new therapies, or new technologies. I wish the general public understood just how hard it is to make a new medicine-the time, the cost, the many areas of science that must come together. I wish the general public were more aware of the size and scale of the social and economic impact of brain disorders and placed the same urgency around cures as, say, oncology.
To tackle your favorite research question, is there a tool that either needs to be developed or is currently available that could be implemented in a novel way? I tend to think a lot about human neurobiology and its application to clinical development. I would love to see a more systematic and creative application of digital tools, devices, and data streams to replace classical clinical scales. I would also like to see new tools or technologies that can achieve neuronal cell-type-specific manipulation in the human brain.
Do you have a favorite anecdote from doing science that you would like to share (perhaps a key discovery moment)? Every discovery has a story behind it. In one project I pursued as a graduate student in Rick Huganir's laboratory at Johns Hopkins, I was looking for proteins that selectively bound to one specific splice variant of an NMDA receptor subunit in a semi-unbiased manner. In one of my first experiments looking at proteins that coimmunoprecipitated with one splice variant but not another, I was finishing up the experiment over the weekend and realized that I was out of my stock solution of EGTA. This was before the days of buying stock solutions, so anyone who has ever made a stock solution of EGTA will know that it takes a long time and requires constant pH adjustment to dissolve the EGTA to get to 0.5 M or so. Being the weekend and it getting rather late, I decided to leave out the EGTA. As it turned out, one of the ''unbiased'' proteins I then found after band purification and protein sequencing was calmodulin, whose binding to the NMDA receptor is calcium dependent and would not have been identified had I included EGTA. This calmodulin binding ended up being
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Biogen an important mechanism of calciumdependent regulation of NMDA receptors, subsequently likewise shown to be a quite conserved mechanism for ion channel regulation such as L-type calcium channels and others. A bit of serendipity can help the prepared mind.
Another favorite anecdote was that as a young assistant professor, I was working on neuronal membrane trafficking and specifically looking to see the extent to which NMDA-type glutamate receptors undergo endocytosis. I had developed some biotinylation-based methods to investigate this in cultured primary cortical neurons, which was tricky but powerful. In this particular experimental system (mature cultured rat cortical neurons), try as I might, I could find very little evidence of NMDA receptor endocytosis under most conditions. Fortunately, I had a bit of brainstorm to simply strip and reprobe my immunoblots for other receptors and ion channels, and lo and behold found that the related AMPAtype glutamate receptors had a much more striking and regulated endocytosis. This observation spawned an entire research direction for years to come in my lab investigating the postsynaptic machinery for membrane trafficking.
As an academic faculty member, I stayed active in the laboratory doing my own experiments for the first 8 years or so, and this kept me aware of the daily trials, tribulations, and triumphs of students and postdocs in the lab. As a senior R&D leader in biopharma, I still keep a desk in the lab. I think there is great value in staying close both to primary data and to the actual experimental process; it is that proximity that builds scientific intuition over time.
What has been the highlight of your career? A big highlight of my career has been working with and training a lot of really great scientists. I get inspired watching young scientists grapple with and ultimately solve tough questions, and seeing the intellectual and professional growth that accompanies experimental work over time.
Another highlight for me in my industry career has been seeing scientific programs that started out as pure discovery projects lead to molecules that get into the clinic and show clinical results with real potential to benefit patients. It renews my belief in science as a driver of social impact.
Who were your key early influences? I owe a great deal to my PhD advisor Rick Huganir, who kept an often disgruntled graduate student focused and encouraged, instilled an excitement about science, and continues to be a source of wisdom and advice. I was heavily influenced by Dale Purves, who as founding Chair of the Department of Neurobiology at Duke took the dubious step of hiring me into the department without much postdoc experience, and who served as an example to me of someone willing to take risks, change fields and directions, and do so with deep rigor at every step. I derived considerable scientific inspiration from my late Duke colleague Larry Katz whose creativity and energy was simply infectious. Early in my industry career, I was highly influenced by Rod MacKenzie at Pfizer and Tamas Bartfai at Scripps, who both went out of their way to teach me the art and science of drug discovery and development, and challenged me over and over to get out of my comfort zone (not an easy thing for a former full Professor!). I have been fortunate to have many superb mentors at every career stage (including now), and it has reinforced the view in my mind that mentorship in science is a life-long, two-way endeavor that is a critical ingredient of a successful career.
What's your favorite experiment? I will go old school molecular biology. My favorite experiment of all time is that of Matthew Meselson and Frank Stahl demonstrating that DNA undergoes semi-conservative replication. It is simple, elegant, definitive, and answered an absolutely fundamental question. Were that all experiments could meet these criteria! What motivated you to become a scientist? Mine is likely a common story. Although I do not have other scientists or physicians in the family, I was just the kind of kid who liked collecting insects, looking under rocks, mixing chemicals, looking through telescopes, and playing with my starter microscope and electronics set. I came hard wired as a nerd.
What is your view on big datagathering collaborations as opposed to hypothesis-driven research by small groups? I see the need for both large-scale science that brings together teams and disciplines to tackle defined big problems, and for the individual laboratories that follow curiosity into unexpected areas. Both are essential, but for different reasons. Big science often fails to find the new hidden gem and tends to avoid the controversial, obscure, or heretical areas of research where paradigm shifts happen. On the other hand, individual laboratories operate as boutiques of a sort, can work in isolation, and are not equipped or structured to address large, multidisciplinary projects that are required to build major scientific or technology infrastructure or confront global challenges. The key is getting the right balance.
What do you think are the biggest problems/challenge science as a whole is facing today? I see basic scientific literacy and education as a big problem facing science as a whole. Among biomedical sciences, brain science in particular is exploding in terms of knowledge, technology, and social impact. Harnessing the full potential of brain science, deploying that knowledge effectively and appropriately, and supporting continued investment in the scientific endeavor requires that we get better at teaching, training, and community engagement.
Another emerging challenge for science as I see it is how data are distributed, vetted, and accessed. In an era of instant communication, Twitter feeds, real-time blogs, and 24/7 information cycles, it is surprising how much of biomedicine relies on 19 th century models of peer review and publication, and how slow the process continues to be from primary observation to broad dissemination. As the pace of scientific advance accelerates, we need to continue finding creative ways to quicken the tempo of data production, review, and diffusion, and structure the incentive systems of scientific institutions accordingly. Neuroscience is inherently multi-disciplinary. I am encouraged by the influx of scientists, engineers, theoreticians, economists, social scientists, molecular biologists, chemists, and physicists into neuroscience. There is hardly a field today that does not have a subfield with the prefix ''neuro'' in front of it, and this is all for the better. At some level, this coalescence is not surprising as neuroscience remains one of the major expanses of uncharted territory on the map of human knowledge. I view the crosstalk with quantitative disciplines to be particularly important.
Where do you see the strongest potential for progress and new breakthroughs in Neuroscience?
In the coming years, we will have more complete connectomes of nervous systems (or at least parts of nervous systems). We will have significant advance in the human genetics of complex brain disorders and behavioral traits. We will have the first therapeutic approaches to truly impact neurodegenerative diseases. We will have an expanding repertoire of neuroprosthetics and brain-machine interfaces that restore and augment function. It is hard not to be excited about the breakthroughs in neuroscience that we will see in the next decade.
What advice do you find yourself giving to your students and postdocs? My first piece of advice is to have fun, and keep in mind what a privilege it is to do science for a living. I usually advise students and postdocs to pick their advisor rather than strictly their project. Selecting an advisor requires a personality match and there is no easy formula, but the right advisor can make even the most seemingly boring project come to life, and vice versa. I tell young scientists to be fearless and take risks, and aim to tackle big questions, because that is the route to real impact. I encourage students and postdocs to challenge dogma and not assume that established scientists in the field have gotten things right. I like to remind students that most experiments fail, but that it only takes one really great experiment to change the world.
How do you find inspiration?
I get inspired by data, and seeing results that no one (or very few people) have seen before. I find inspiration reading about the lives of prominent scientists as it creates an arc of continuity to the contemporary scientific endeavor. I am also inspired by music, particularly creating music, as it draws upon a search for beauty and form not so different from doing science. , so I won't repeat all of that here. Overcoming the challenges of a major career change like that required a bit of resilience and flexibility, but also a willingness to learn, adapt, practice, accept feedback, and above all take risks.
What career paths did you consider other than a scientist? For a while in high school, I was close to considering a career as a professional musician, but my Midwestern practicality got the better of me, as did my growing amazement with math, physics, and chemistry, and the latter elements won out. In the midst of graduate school during that typical dark period of the second or third year when the light at the tunnel has yet to appear, I contemplated becoming a management consultant. Thank goodness I came to my senses. Later on, I completed the MD/PhD program at Johns Hopkins and, like all MD/ PhD students, wrestled with the relative pursuit of research and clinical activities, and nearly dropped out of the PhD portion to go down the physician route. But fortunately, I stuck it out with a great PhD advisor, and I ultimately realized how much I loved being in the laboratory conducting experiments, to the point where I didn't pursue further clinical training. Somehow, the most interesting career paths are often the most winding and untrodden.
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